A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial*

TY - JOUR

T1 - A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis

T2 - 24-week efficacy and safety results from a randomized, double-blinded trial*

AU - the IXORA-R Study Group

AU - Blauvelt, A.

AU - Leonardi, C.

AU - Elewski, B.

AU - Crowley, J. J.

AU - Guenther, L. C.

AU - Gooderham, M.

AU - Langley, R. G.

AU - Vender, R.

AU - Pinter, A.

AU - Griffiths, C. E.M.

AU - Tada, Y.

AU - Elmaraghy, H.

AU - Lima, R. G.

AU - Gallo, G.

AU - Renda, L.

AU - Burge, R.

AU - Park, S. Y.

AU - Zhu, B.

AU - Papp, K.

N1 - Publisher Copyright: © 2020 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists

PY - 2021/6

Y1 - 2021/6

UR - http://www.scopus.com/inward/record.url?scp=85093966402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85093966402&partnerID=8YFLogxK

U2 - 10.1111/bjd.19509

DO - 10.1111/bjd.19509

M3 - Article

C2 - 32880909

AN - SCOPUS:85093966402

SN - 0007-0963

VL - 184

SP - 1047

EP - 1058

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 6

ER -